pembrolizumab
merck
['pembro']
 are there major differences in patients lost to follow-up for positive study vs negative study; or major prognostic imbalances in study arms (with more favorable prognostic pts in the pembro arm, eg number of major comorbidities, stage, etc ) that could explain findings? #esmo22
Translational Medical Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data) @OncoAlert. Motto: "Let's make a difference". Views mine.